Literature DB >> 27775474

Characterization of the Antibody Response after Cervical Spinal Cord Injury.

Antigona Ulndreaj1,2, Apostolia Tzekou1, Andrea J Mothe1, Ahad M Siddiqui1, Rachel Dragas1,2, Charles H Tator1,2,3,4, Emina E Torlakovic5, Michael G Fehlings1,2,3,4.   

Abstract

The immune system plays a critical and complex role in the pathobiology of spinal cord injury (SCI), exerting both beneficial and detrimental effects. Increasing evidence suggests that there are injury level-dependent differences in the immune response to SCI. Patients with traumatic SCI have elevated levels of circulating autoantibodies against components of the central nervous system, but the role of these antibodies in SCI outcomes remains unknown. In rodent models of mid-thoracic SCI, antibody-mediated autoimmunity appears to be detrimental to recovery. However, whether autoantibodies against the spinal cord are generated following cervical SCI (cSCI), the most common level of injury in humans, remains undetermined. To address this knowledge gap, we investigated the antibody responses following cSCI in a rat model of injury. We found increased immunoglobulin G (IgG) and IgM antibodies in the spinal cord in the subacute phase of injury (2 weeks), but not in more chronic phases (10 and 20 weeks). At 2 weeks post-cSCI, antibodies were detected at the injury epicenter and co-localized with the astroglial scar and neurons of the ventral horn. These increased levels of antibodies corresponded with enhanced activation of immune responses in the spleen. Higher counts of antibody-secreting cells were observed in the spleen of injured rats. Further, increased levels of secreted IgG antibodies and enhanced proliferation of T-cells in splenocyte cultures from injured rats were found. These findings suggest the potential development of autoantibody responses following cSCI in the rat. The impact of the post-traumatic antibody responses on functional outcomes of cSCI is a critical topic that requires further investigation.

Entities:  

Keywords:  IgG/IgM immunoglobulins; antibody-secreting cells (ASCs); astrocytes; autoantibodies; cervical spinal cord injury (cSCI)

Mesh:

Substances:

Year:  2016        PMID: 27775474      PMCID: PMC5359645          DOI: 10.1089/neu.2016.4498

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  69 in total

1.  Autoimmune T cells as potential neuroprotective therapy for spinal cord injury.

Authors:  E Hauben; U Nevo; E Yoles; G Moalem; E Agranov; F Mor; S Akselrod; M Neeman; I R Cohen; M Schwartz
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

2.  Elevated serum titers of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury.

Authors:  K C Hayes; T C L Hull; G A Delaney; P J Potter; K A J Sequeira; K Campbell; P G Popovich
Journal:  J Neurotrauma       Date:  2002-06       Impact factor: 5.269

Review 3.  Epidemiology, demographics, and pathophysiology of acute spinal cord injury.

Authors:  L H Sekhon; M G Fehlings
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-15       Impact factor: 3.468

4.  Natural and induced B-1 cell immunity to infections raises questions of nature versus nurture.

Authors:  Nicole Baumgarth; Elizabeth E Waffarn; Trang T T Nguyen
Journal:  Ann N Y Acad Sci       Date:  2015-06-09       Impact factor: 5.691

5.  Chronic spinal cord injury impairs primary antibody responses but spares existing humoral immunity in mice.

Authors:  Michael A Oropallo; Katherine S Held; Radhika Goenka; Sifat A Ahmad; Patrick J O'Neill; Oswald Steward; Thomas E Lane; Michael P Cancro
Journal:  J Immunol       Date:  2012-04-20       Impact factor: 5.422

6.  Injury-related spinal cord astrocytes are immunoglobulin-positive (IgM and/or IgG) at different time periods in the regenerative process.

Authors:  J J Bernstein; W J Goldberg
Journal:  Brain Res       Date:  1987-11-17       Impact factor: 3.252

7.  Serum IgM anti-GM1 ganglioside antibodies in lower motor neuron syndromes.

Authors:  I Niebroj-Dobosz; P Janik; H Kwieciński
Journal:  Eur J Neurol       Date:  2004-01       Impact factor: 6.089

8.  Immunoglobulin G (IgG) attenuates neuroinflammation and improves neurobehavioral recovery after cervical spinal cord injury.

Authors:  Dung Hoang Nguyen; Newton Cho; Kajana Satkunendrarajah; James W Austin; Jian Wang; Michael G Fehlings
Journal:  J Neuroinflammation       Date:  2012-09-21       Impact factor: 8.322

9.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

Review 10.  Treatment of spinal cord injury with intravenous immunoglobulin G: preliminary evidence and future perspectives.

Authors:  Apostolia Tzekou; Michael G Fehlings
Journal:  J Clin Immunol       Date:  2014-04-11       Impact factor: 8.317

View more
  13 in total

Review 1.  Musculoskeletal Health in the Context of Spinal Cord Injury.

Authors:  Jillian M Clark; David M Findlay
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

2.  Repositioning Flubendazole for Spinal Cord Injury.

Authors:  Chen Guang Yu; Vimala Bondada; Sarbani Ghoshal; Ranjana Singh; Christina K Pistilli; Kavi Dayaram; Hina Iqbal; Madison Sands; Kate L Davis; Subarrao Bondada; James W Geddes
Journal:  J Neurotrauma       Date:  2019-03-15       Impact factor: 5.269

3.  Extensive somatosensory and motor corticospinal sprouting occurs following a central dorsal column lesion in monkeys.

Authors:  Karen M Fisher; Alayna Lilak; Joseph Garner; Corinna Darian-Smith
Journal:  J Comp Neurol       Date:  2018-09-25       Impact factor: 3.215

4.  Serial plasma DNA levels as predictors of outcome in patients with acute traumatic cervical spinal cord injury.

Authors:  Hung-Chen Wang; Yu-Tsai Lin; Shih-Yuan Hsu; Nai-Wen Tsai; Yun-Ru Lai; Ben Yu-Jih Su; Chia-Te Kung; Cheng-Hsien Lu
Journal:  J Transl Med       Date:  2019-10-01       Impact factor: 5.531

5.  Inhibition of Bruton Tyrosine Kinase Reduces Neuroimmune Cascade and Promotes Recovery after Spinal Cord Injury.

Authors:  Chen Guang Yu; Vimala Bondada; Hina Iqbal; Kate L Moore; John C Gensel; Subbarao Bondada; James W Geddes
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

Review 6.  Promising neuroprotective strategies for traumatic spinal cord injury with a focus on the differential effects among anatomical levels of injury.

Authors:  Antigona Ulndreaj; Anna Badner; Michael G Fehlings
Journal:  F1000Res       Date:  2017-10-30

7.  Splenic involvement in umbilical cord matrix-derived mesenchymal stromal cell-mediated effects following traumatic spinal cord injury.

Authors:  Anna Badner; Justin Hacker; James Hong; Mirriam Mikhail; Reaz Vawda; Michael G Fehlings
Journal:  J Neuroinflammation       Date:  2018-08-03       Impact factor: 8.322

8.  Elevated Autoantibodies in Subacute Human Spinal Cord Injury Are Naturally Occurring Antibodies.

Authors:  Angel Arevalo-Martin; Lukas Grassner; Daniel Garcia-Ovejero; Beatriz Paniagua-Torija; Gemma Barroso-Garcia; Alba G Arandilla; Orpheus Mach; Angela Turrero; Eduardo Vargas; Monica Alcobendas; Carmen Rosell; Maria A Alcaraz; Silvia Ceruelo; Rosa Casado; Francisco Talavera; Ramiro Palazón; Nuria Sanchez-Blanco; Doris Maier; Ana Esclarin; Eduardo Molina-Holgado
Journal:  Front Immunol       Date:  2018-10-11       Impact factor: 7.561

9.  Methylprednisolone treatment enhances early recovery following surgical decompression for degenerative cervical myelopathy without compromise to the systemic immune system.

Authors:  Pia M Vidal; Antigona Ulndreaj; Anna Badner; James Hong; Michael G Fehlings
Journal:  J Neuroinflammation       Date:  2018-08-06       Impact factor: 8.322

10.  Effects of experimental cervical spinal cord injury on peripheral adaptive immunity.

Authors:  Antigona Ulndreaj; Apostolia Tzekou; Ahad M Siddiqui; Michael G Fehlings
Journal:  PLoS One       Date:  2020-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.